Concurrent FDA approval and the establishment of Medicare coverage will propel Next generation sequencing squarely into the mainstream of oncology practice, said Vincent Miller, chief medical officer of Foundation Medicine Inc.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe